INDEPENDENT THINKING. TRACEABLE EVIDENCE.Research edition · 29 October 2026
Modern DosingTHE PRACTITIONER’S PERSPECTIVEA clearer view of
the peptide economy ↗
The provider file / Dossier 282
RESEARCH DOSSIER / NOT AN ENDORSEMENT

SurpassMD

A dated business research record, with the original field-level evidence labels kept intact.

Source snapshot: 2026-10-29. “Verified” below is the source dataset author’s label—not an independent license, safety, quality or clinical audit by Modern Dosing. These pages are excluded from search indexing until reviewed.
Positioning & service claimspartial

'SurpassMD. Medical weight loss, physician-led. Launching Summer 2026' - coming-soon page observed 20 Oct 2026 (stale date). Discovery coverage describes a metabolic-health telehealth built around clinician-guided GLP-1 care (compounded and oral semaglutide).

Audienceread

US weight-loss patients (intended).

Pricing & termsnot_found

Not publicly priced; site shows only a coming-soon page.

Clinical relationshipspartial

Physician-led positioning on placeholder page; no clinical network disclosed.

Pharmacy & fulfillmentnot_found

Not established.

    Advertising snapshotpartial

    No attributable ads found in Google, Meta or LinkedIn public libraries on 20 Oct 2026. See dated channel evidence.

    Founding yearpartial

    Coming-soon page says 'Launching Summer 2026' (stale as of 20 Oct 2026).

    Founderspartial

    Founded by app-industry veteran Vivek Girotra, per App Growth Summit coverage.

    Location & entity contextnot_found

    Not stated on pages reviewed.

      Search visibility samplenot_found

      Not assessed in this pass.

        THE MODERN DOSING WEEKLY

        The peptide news
        that changes your week.

        Evidence-backed developments. The moves that matter. What each means for your practice or business—in one weekly email.